Business
Design Therapeutics Appoints Justin Gover to Board of Directors
CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately. Mr. Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding Chief Executive Officer of GW Pharmaceuticals plc, guiding the company
About this update from Jazz Pharmaceuticals Plc
[{"type":"image","alt":"Design Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Design Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":72,"url":"https://media.zenfs.com/en/globenewswire.com/756f7355ee3593505f98a201ce9c55ac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8ohx5nSh.dNqlWjduPDJgw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/756f7355ee3593505f98a201ce9c55ac","width":300,"height":72}},"lazy":false},{"type":"text","content":"CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately.","length":313,"tagName":"p"},{"type":"text","content":"Mr. Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding Chief Executive Officer of GW Pharmaceuticals plc, guiding the company for over two decades, from inception through its strategic $7 billion acquisition by Jazz Pharmaceuticals in 2021. During his tenure, GW grew into a fully integrated global biotech organization and successfully commercialized Epidiolex® (cannabidiol), which is approved in the U.S. and Europe for the treatment of childhood onset epilepsies.","length":527,"tagName":"p"},{"type":"text","content":"As part of this transition, Dr. Arsani William, Managing Partner and Chief Investment Officer of Logos Capital, stepped down from the Board, effective September 9, 2025. Since joining in 2021, Dr. William has provided strategic counsel that has been instrumental to Design’s progress, including guiding the company through its successful 2021 initial public offering, supporting the advancement of its clinical pipeline, and strengthening its governance as a public company.","length":474,"tagName":"p"},{"type":"text","content":"“Justin brings a deep understanding of our industry and a focus on executional excellence to the Board at this important time for Design,” said Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics. “His proven ability to translate innovative science into important medicines, along with his experience building a world...